0N4A.L - Vivesto AB

LSE - LSE Delayed Price. Currency in SEK

Vivesto AB

Gustav III:s Boulevard 46
5th floor
Solna 169 73
46 18 50 54 40

Full Time Employees18

Key Executives

NameTitlePayExercisedYear Born
Mr. Erik Kinnmann Assoc. Prof., M.B.A., M.D., Ph.D.Chief Exec. OfficerN/AN/A1958
Mr. Robert MaioranaHead of Accounting & Acting CFON/AN/A1960
Mr. Kai WilkinsonChief Technical OfficerN/AN/A1981
Mr. Urban EkelundIR Mang.N/AN/AN/A
Mr. John T. CosbyHead of Regulatory AffairsN/AN/A1962
Mr. Dzianis BabrouHead of Product Devel.N/AN/AN/A
Mr. Henrik RönnbergChief Medical Officer of Animal HealthN/AN/AN/A
Maria Nilsson HagbergHead of Regulatory AffairsN/AN/AN/A
Ms. Johanna RostinChief Regulatory OfficerN/AN/A1967
Ms. Kia BengtssonHead of Clinical Devel.N/AN/A1969
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Corporate Governance

Vivesto AB’s ISS Governance QualityScore as of June 1, 2023 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.